Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Raab

Showing results (401-410 of 427) with videos related to

Pageof 43
Sort By:
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Science Immunology|February 7, 2025
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myelomaRaphael Lutz, Alexandra M Poos, Llorenç Solé-Boldo, et al.
Nature Medicine|January 15, 2026
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myelomaHolly Lee, Sungwoo Ahn, Gerone A Gonzales, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Blood Cancer Discovery|June 12, 2026
Genomic features do not account for differences in multiple myeloma risk by ancestryKylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, et al.
Leukemia|August 2, 2017
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trialH Goldschmidt, H M Lokhorst, E K Mai, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 TrialElias K Mai, Uta Bertsch, Ema Pozek, et al.
Leukemia|June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III studyKatharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
Leukemia|July 4, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Pageof 43

Showing results (401-410 of 427) with videos related to

Sort By:
Pageof 43
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Science Immunology|February 7, 2025
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myelomaRaphael Lutz, Alexandra M Poos, Llorenç Solé-Boldo, et al.
Nature Medicine|January 15, 2026
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myelomaHolly Lee, Sungwoo Ahn, Gerone A Gonzales, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Blood Cancer Discovery|June 12, 2026
Genomic features do not account for differences in multiple myeloma risk by ancestryKylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, et al.
Leukemia|August 2, 2017
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trialH Goldschmidt, H M Lokhorst, E K Mai, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 TrialElias K Mai, Uta Bertsch, Ema Pozek, et al.
Leukemia|June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III studyKatharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
Leukemia|July 4, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Pageof 43